Biocryst Pharmaceuticals (BCRX) Cash & Equivalents (2010 - 2026)

Biocryst Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $171.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 58865.98% year-over-year to $171.6 million; the trailing twelve-month figure through Mar 2026 stood at $171.6 million (up 58865.98% YoY), and the FY2025 full-year result was $89.7 million, down 14.3% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $171.6 million, up from $89.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $246.9 million in Q3 2022, with the low at $291000.0 in Q1 2025.
• Historically, Cash & Equivalents has averaged $85.3 million across 5 years, with a median of $89.7 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 99.71% — and 2026, when it soared 58865.98%.
• Biocryst Pharmaceuticals' Cash & Equivalents stood at $1.5 million in 2022, then soared by 7416.51% to $110.6 million in 2023, then slipped by 5.36% to $104.7 million in 2024, then declined by 14.3% to $89.7 million in 2025, then surged by 91.22% to $171.6 million in 2026.
• The last three Cash & Equivalents figures came in at $171.6 million (Q1 2026), $89.7 million (Q4 2025), and $84.1 million (Q3 2025), per Business Quant data.